These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 27173253)
1. Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer. Zheng DL; Tang GD; Chen YN; Zhang T; Qin MB Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173253 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy. Mo J; Luo M; Cui J; Zhou S Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845 [TBL] [Abstract][Full Text] [Related]
3. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer. Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265 [TBL] [Abstract][Full Text] [Related]
4. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer. Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599 [TBL] [Abstract][Full Text] [Related]
5. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer. Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397 [TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer. Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228 [TBL] [Abstract][Full Text] [Related]
7. ERCC1 and ERCC2 variants predict survival in gastric cancer patients. Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723 [TBL] [Abstract][Full Text] [Related]
8. Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients. Zhong G; Li HK; Shan T; Zhang N Genet Mol Res; 2015 Dec; 14(4):17228-34. PubMed ID: 26681216 [TBL] [Abstract][Full Text] [Related]
9. Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer. Bai Y; Wang L; Li G; Fang X; Li Y; Yang S Int J Clin Exp Pathol; 2015; 8(10):13367-73. PubMed ID: 26722542 [TBL] [Abstract][Full Text] [Related]
10. Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer. Zhao F; Shang Y; Zeng C; Gao D; Li K Int J Clin Exp Pathol; 2015; 8(9):11579-86. PubMed ID: 26617894 [TBL] [Abstract][Full Text] [Related]
11. Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer. He MG; Zheng K; Tan D; Wang ZX Genet Mol Res; 2016 Mar; 15(1):. PubMed ID: 27051038 [TBL] [Abstract][Full Text] [Related]
12. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma. Cao ZH; Yin HP; Jiang N; Yu B Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951 [TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma. Sun Y; Wu Y; Li W; Kong Z; Zou X Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355 [TBL] [Abstract][Full Text] [Related]
14. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma. Zhang Q; Lv LY; Li BJ; Zhang J; Wei F Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354 [TBL] [Abstract][Full Text] [Related]
15. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy. Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858 [TBL] [Abstract][Full Text] [Related]
16. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907 [TBL] [Abstract][Full Text] [Related]
17. Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma. Wang MJ; Zhu Y; Guo XJ; Tian ZZ Genet Mol Res; 2015 Sep; 14(3):11652-7. PubMed ID: 26436406 [TBL] [Abstract][Full Text] [Related]
18. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients. Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176 [TBL] [Abstract][Full Text] [Related]
19. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma. Ji WP; He NB Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792 [TBL] [Abstract][Full Text] [Related]
20. ERCC1 and ERCC2 haplotype modulates induced BPDE-DNA adducts in primary cultured lymphocytes. Lu X; Liu Y; Yu T; Xiao S; Bao X; Pan L; Zhu G; Cai Y; Liu Q; Jin C; Yang J; Wu S; An L; van der Straaten T PLoS One; 2013; 8(4):e60006. PubMed ID: 23593158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]